Synonym
Viloxazine; ICI 58,834; ICI-58,834; ICI58,834; ICI 58834; ICI-58834; ICI58834; SPN-812; SPN 812; SPN812;
IUPAC/Chemical Name
2-[(2-Ethoxyphenoxy)methyl]morpholine acetate
InChi Key
MOGNHKOHVIIIBL-UHFFFAOYSA-N
InChi Code
InChI=1S/C13H19NO3.C2H4O2/c1-2-15-12-5-3-4-6-13(12)17-10-11-9-14-7-8-16-11;1-2(3)4/h3-6,11,14H,2,7-10H2,1H3;1H3,(H,3,4)
SMILES Code
CCOC1=CC=CC=C1OCC2CNCCO2.CC(O)=O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
297.35
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Pérez-Baeza M, Escuder-Gilabert L, Martín-Biosca Y, Sagrado S, Medina- Hernández MJ. Potential of sodium dodecyl sulfate micellar solutions as eluents in magnetic dispersive micro-solid phase extraction with polydopamine-coated magnetite nanoparticles. Application to antidepressant drugs. J Chromatogr A. 2022 Aug 19;1680:463430. doi: 10.1016/j.chroma.2022.463430. Epub ahead of print. PMID: 36030567.
2: Haddad HW, Hankey PB, Ko J, Eswani Z, Bhatti P, Edinoff AN, Kaye AM, Kaye AD. Viloxazine, a Non-stimulant Norepinephrine Reuptake Inhibitor, for the Treatment of Attention Deficit Hyperactivity Disorder: A 3 Year Update. Health Psychol Res. 2022 Jul 28;10(3):37018. doi: 10.52965/001c.37018. PMID: 35910243; PMCID: PMC9334155.
3: Nasser A, Hull JT, Chaturvedi SA, Liranso T, Odebo O, Kosheleff AR, Fry N, Cutler AJ, Rubin J, Schwabe S, Childress A. A Phase III, Randomized, Double- Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder. CNS Drugs. 2022 Aug;36(8):897-915. doi: 10.1007/s40263-022-00938-w. Epub 2022 Jul 27. PMID: 35896943; PMCID: PMC9328182.
4: Kameg B. Viloxazine ER (Qelbree®): A New Non-Stimulant Option in the Treatment of Pediatric Attention-Deficit/Hyperactivity Disorder. J Psychosoc Nurs Ment Health Serv. 2022 Jul;60(7):7-9. doi: 10.3928/02793695-20220610-04. Epub 2022 Jul 1. PMID: 35858173.
5: Childress A, Burton S. Evaluating the pharmacokinetics of extended release viloxazine in the treatment of children with attention-deficit/hyperactivity disorder. Expert Opin Drug Metab Toxicol. 2022 Jun;18(6):357-366. doi: 10.1080/17425255.2022.2103406. Epub 2022 Jul 25. PMID: 35848085.
6: Mather K, Condren M. Extended-Release Viloxazine for Children and Adolescents With Attention Deficit Hyperactivity Disorder. J Pediatr Pharmacol Ther. 2022;27(5):409-414. doi: 10.5863/1551-6776-27.5.409. Epub 2022 Jul 6. PMID: 35845566; PMCID: PMC9268104.
7: Mathew BM, Pellegrini MV. Viloxazine. 2022 Jun 16. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 35015448.
8: Newcorn JH, Krone B, Dittmann RW. Nonstimulant Treatments for ADHD. Child Adolesc Psychiatr Clin N Am. 2022 Jul;31(3):417-435. doi: 10.1016/j.chc.2022.03.005. Epub 2022 May 11. PMID: 35697393.
9: Lorman WJ. Viloxazine (Qelbree™): A Nonstimulant Extended-Release Capsule for the Treatment of Attention Deficit Hyperactivity Disorder. J Addict Nurs. 2022 Apr-Jun 01;33(2):114-115. doi: 10.1097/JAN.0000000000000459. PMID: 35640214.
10: Singh A, Balasundaram MK, Singh A. Viloxazine for Attention-Deficit Hyperactivity Disorder: A Systematic Review and Meta-analysis of Randomized Clinical Trials. J Cent Nerv Syst Dis. 2022 May 20;14:11795735221092522. doi: 10.1177/11795735221092522. PMID: 35615643; PMCID: PMC9125110.
